Sub-Q Tocilizumab Gives Durable Long-Term Responses in JIA :

Patients with juvenile idiopathic arthritis achieved long-term disease control with subcutaneous tocilizumab treatment, without any new safety concerns, in an LTE study of two trials.

Related Keywords

Cincinnati , Ohio , United States , Herminei Brunner , , International League , Cincinnati Children , Hospital Medical Center , Juvenile Rheumatoid Arthritis , Uvenile Ra , Juvenile Idiopathic Arthritis , Arthritis , Oint Inflammation , Rheumatoid Arthritis Ra , Heumatoid Arthritis Ra , Biologic Therapy , Iologics , Remission , Hospitals , Intravenous , V Intravenous , Intravenous Route ,